Pulmonary hypertension in chronic hemolytic anemias: Pathophysiology and treatment
Open Access
- 27 February 2018
- journal article
- review article
- Published by Elsevier BV in Respiratory Medicine
- Vol. 137, 191-200
- https://doi.org/10.1016/j.rmed.2018.02.020
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- Global Burden of Sickle Cell Anaemia in Children under Five, 2010–2050: Modelling Based on Demographics, Excess Mortality, and InterventionsPLoS Medicine, 2013
- Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertensionHaematologica, 2013
- Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacityBlood, 2011
- NT‐pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell diseaseBritish Journal of Haematology, 2011
- Sickle-cell diseaseThe Lancet, 2010
- Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studiesBritish Journal of Haematology, 2010
- Vascular complications after splenectomy for hematologic disordersBlood, 2009
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Hemodynamic and Functional Assessment of Patients with Sickle Cell Disease and Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemiaHeart, 2006